Total Payments
$4,005
2024 Payments
$581.59
Companies
19
Transactions
346
Medicare Patients
664
Medicare Billing
$71,011
Payment Breakdown by Category
Food & Beverage$3,830 (95.6%)
Education$175.07 (4.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,830 | 343 | 95.6% |
| Education | $175.07 | 3 | 4.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $683.66 | 206 | $0 (2024) |
| ViiV Healthcare Company | $626.29 | 12 | $0 (2024) |
| Gilead Sciences, Inc. | $506.76 | 10 | $0 (2023) |
| Merck Sharp & Dohme LLC | $288.52 | 15 | $0 (2024) |
| Astellas Pharma US Inc | $273.32 | 3 | $0 (2019) |
| Insmed, Inc. | $270.28 | 5 | $0 (2023) |
| Allergan Inc. | $263.52 | 56 | $0 (2019) |
| Theratechnologies Inc. | $193.69 | 4 | $0 (2022) |
| Melinta Therapeutics, LLC | $192.44 | 5 | $0 (2024) |
| The Medicines Company | $165.35 | 12 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $581.59 | 66 | ViiV Healthcare Company ($242.94) |
| 2023 | $831.39 | 90 | AbbVie Inc. ($273.54) |
| 2022 | $579.09 | 86 | ABBVIE INC. ($254.10) |
| 2021 | $158.25 | 8 | ViiV Healthcare Company ($41.80) |
| 2020 | $252.06 | 5 | Insmed, Inc. ($116.30) |
| 2019 | $1,030 | 68 | ViiV Healthcare Company ($266.32) |
| 2018 | $331.53 | 6 | Gilead Sciences, Inc. ($219.46) |
| 2017 | $241.24 | 17 | The Medicines Company ($165.35) |
All Payment Transactions
346 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | ABBVIE INC. | TEFLARO (Drug), AVYCAZ, DALVANCE | Food and Beverage | In-kind items and services | $2.49 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/10/2024 | ABBVIE INC. | TEFLARO (Drug), AVYCAZ, DALVANCE | Food and Beverage | In-kind items and services | $2.45 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/12/2024 | ABBVIE INC. | TEFLARO (Drug), AVYCAZ, DALVANCE | Food and Beverage | In-kind items and services | $1.90 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/12/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE, AVYCAZ | Food and Beverage | In-kind items and services | $1.85 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/05/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $110.40 | General |
| Category: HIV | ||||||
| 11/05/2024 | ABBVIE INC. | AVYCAZ (Drug), DALVANCE, TEFLARO | Food and Beverage | In-kind items and services | $2.52 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/05/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE, AVYCAZ | Food and Beverage | In-kind items and services | $2.04 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/04/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO | Food and Beverage | In-kind items and services | $31.79 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/29/2024 | ABBVIE INC. | AVYCAZ (Drug), DALVANCE, TEFLARO | Food and Beverage | In-kind items and services | $1.97 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/29/2024 | ABBVIE INC. | AVYCAZ (Drug), DALVANCE, TEFLARO | Food and Beverage | In-kind items and services | $1.78 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/29/2024 | ABBVIE INC. | AVYCAZ (Drug), DALVANCE, TEFLARO | Food and Beverage | In-kind items and services | $0.25 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/08/2024 | ABBVIE INC. | DALVANCE (Drug), TEFLARO, AVYCAZ | Food and Beverage | In-kind items and services | $2.26 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/08/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE, AVYCAZ | Food and Beverage | In-kind items and services | $1.51 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/10/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $2.67 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/10/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $1.72 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/09/2024 | ABBVIE INC. | TEFLARO (Drug), AVYCAZ, DALVANCE | Food and Beverage | In-kind items and services | $22.52 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/27/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $2.84 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/27/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $1.91 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/30/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $2.50 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/30/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $1.84 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/29/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug) | Food and Beverage | In-kind items and services | $26.49 | General |
| Category: ANTIFUNGALS | ||||||
| 07/23/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $2.74 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/23/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $1.91 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/23/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $1.04 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/11/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $2.15 | General |
| Category: ANTI-INFECTIVE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 125 | 160 | $33,091 | $12,170 |
| 2022 | 4 | 116 | 166 | $31,219 | $11,297 |
| 2021 | 6 | 174 | 243 | $51,898 | $18,342 |
| 2020 | 6 | 249 | 323 | $81,718 | $29,203 |
Total Patients
664
Total Services
892
Medicare Billing
$71,011
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 39 | 59 | $9,558 | $3,594 | 37.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 33 | 48 | $8,256 | $3,517 | 42.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 31 | 31 | $9,238 | $3,145 | 34.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 11 | $4,818 | $1,401 | 29.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 11 | 11 | $1,221 | $512.80 | 42.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 40 | 71 | $11,502 | $3,905 | 33.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 36 | 36 | $10,728 | $3,641 | 33.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 25 | 40 | $6,880 | $2,895 | 42.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 15 | 19 | $2,109 | $855.62 | 40.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 67 | 125 | $20,250 | $6,944 | 34.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 42 | 43 | $12,814 | $4,519 | 35.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 24 | 29 | $6,728 | $2,315 | 34.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 13 | 13 | $5,694 | $2,012 | 35.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 12 | 17 | $2,924 | $1,302 | 44.5% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 16 | 16 | $3,488 | $1,250 | 35.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 62 | 62 | $27,156 | $9,833 | 36.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 71 | 73 | $21,754 | $7,778 | 35.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 63 | 113 | $18,306 | $6,444 | 35.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 29 | 45 | $10,440 | $3,704 | 35.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 11 | 12 | $2,064 | $754.14 | 36.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 13 | 18 | $1,998 | $690.98 | 34.6% |
About Dr. Andrew Chao, M.D
Dr. Andrew Chao, M.D is a Infectious Disease healthcare provider based in Augusta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/08/2011. The National Provider Identifier (NPI) number assigned to this provider is 1699062893.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrew Chao, M.D has received a total of $4,005 in payments from pharmaceutical and medical device companies, with $581.59 received in 2024. These payments were reported across 346 transactions from 19 companies. The most common payment nature is "Food and Beverage" ($3,830).
As a Medicare-enrolled provider, Chao has provided services to 664 Medicare beneficiaries, totaling 892 services with total Medicare billing of $71,011. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Augusta, GA
- Active Since 07/08/2011
- Last Updated 11/08/2017
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1699062893
Products in Payments
- AVYCAZ (Drug) $563.72
- DOVATO (Drug) $480.99
- Biktarvy (Drug) $412.44
- DALVANCE (Drug) $216.32
- SYMTUZA (Drug) $201.92
- Arikayce (Drug) $168.94
- TEFLARO (Drug) $167.14
- TROGARZO (Drug) $146.05
- Fetroja (Drug) $144.43
- Rezzayo (Drug) $139.06
- CABENUVA (Biological) $110.40
- PIFELTRO (Drug) $104.90
- CRESEMBA (Drug) $104.33
- SurgX (Device) $96.97
- MINOCIN IV (Drug) $83.50
- ORBACTIV (Drug) $81.85
- EGRIFTA (Drug) $47.64
- DIFICID (Drug) $45.52
- ZERBAXA (Drug) $44.69
- RUKOBIA (Drug) $34.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Augusta
Cheryl Newman, Md, MD
Infectious Disease — Payments: $150,138
Infectious Disease $150,138
John Rissing, Md, MD
Infectious Disease — Payments: $43,837
Infectious Disease $43,837
Dr. Jack Austin, Md, MD
Infectious Disease — Payments: $7,058
Infectious Disease $7,058
Dr. Francisco Hernandez Munoz, M.d, M.D
Infectious Disease — Payments: $4,252
Infectious Disease $4,252
Dr. Kepler Davis, M.d, M.D
Infectious Disease — Payments: $3,326
Infectious Disease $3,326
Jacobo Leon, Md, MD
Infectious Disease — Payments: $1,182
Infectious Disease $1,182